- Home
- FIVN vs BLTE Comparison
FIVN vs BLTE Comparison
Compare FIVN & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- BLTE
- Stock Information
- Founded
- FIVN 2001
- BLTE 2018
- Country
- FIVN United States
- BLTE United States
- Employees
- FIVN N/A
- BLTE N/A
- Industry
- FIVN EDP Services
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- FIVN Technology
- BLTE Health Care
- Exchange
- FIVN Nasdaq
- BLTE Nasdaq
- Market Cap
- FIVN 2.3B
- BLTE 2.1B
- IPO Year
- FIVN 2014
- BLTE 2022
- Fundamental
- Price
- FIVN $26.85
- BLTE $60.48
- Analyst Decision
- FIVN Buy
- BLTE Strong Buy
- Analyst Count
- FIVN 21
- BLTE 4
- Target Price
- FIVN $43.95
- BLTE $96.67
- AVG Volume (30 Days)
- FIVN 1.7M
- BLTE 30.8K
- Earning Date
- FIVN 08-07-2025
- BLTE 08-08-2025
- Dividend Yield
- FIVN N/A
- BLTE N/A
- EPS Growth
- FIVN N/A
- BLTE N/A
- EPS
- FIVN N/A
- BLTE N/A
- Revenue
- FIVN $1,074,633,000.00
- BLTE N/A
- Revenue This Year
- FIVN $11.81
- BLTE N/A
- Revenue Next Year
- FIVN $9.79
- BLTE N/A
- P/E Ratio
- FIVN N/A
- BLTE N/A
- Revenue Growth
- FIVN 14.44
- BLTE N/A
- 52 Week Low
- FIVN $21.04
- BLTE $43.70
- 52 Week High
- FIVN $49.90
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- FIVN 46.55
- BLTE 46.26
- Support Level
- FIVN $26.52
- BLTE $58.55
- Resistance Level
- FIVN $28.02
- BLTE $62.49
- Average True Range (ATR)
- FIVN 1.07
- BLTE 1.81
- MACD
- FIVN -0.20
- BLTE -0.40
- Stochastic Oscillator
- FIVN 27.66
- BLTE 26.19
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.